TWI670058B - 經取代的甘胺酸化合物的共晶及其用途 - Google Patents

Info

Publication number

TWI670058B

TWI670058B TW107101039A TW107101039A TWI670058B TW I670058 B TWI670058 B TW I670058B TW 107101039 A TW107101039 A TW 107101039A TW 107101039 A TW107101039 A TW 107101039A TW I670058 B TWI670058 B TW I670058B

Authority

TW

Taiwan

Prior art keywords

eutectic

crystal

alkyl

disorder

methylglycine

Prior art date

2017-02-13

Links

• Espacenet
• Global Dossier
• Discuss

• 239000013078 crystal Substances 0.000 title claims abstract description 191
• 125000003630 glycyl group Chemical class [H]N([H])C([H])([H])C(*)=O 0.000 title 1
• -1 glycine compound Chemical class 0.000 claims abstract description 208
• 230000005496 eutectics Effects 0.000 claims abstract description 175
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 120
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 115
• 239000004471 Glycine Substances 0.000 claims abstract description 113
• 239000000203 mixture Substances 0.000 claims abstract description 107
• 201000010099 disease Diseases 0.000 claims abstract description 70
• 238000000034 method Methods 0.000 claims abstract description 56
• 208000020016 psychiatric disease Diseases 0.000 claims abstract description 18
• 201000000980 schizophrenia Diseases 0.000 claims abstract description 11
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims abstract description 7
• 206010042458 Suicidal ideation Diseases 0.000 claims abstract description 6
• 206010065604 Suicidal behaviour Diseases 0.000 claims abstract description 5
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 421
• 108010077895 Sarcosine Proteins 0.000 claims description 207
• 125000000217 alkyl group Chemical group 0.000 claims description 205
• FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims description 100
• 125000003342 alkenyl group Chemical group 0.000 claims description 54
• 238000000634 powder X-ray diffraction Methods 0.000 claims description 52
• 208000035475 disorder Diseases 0.000 claims description 49
• 150000001875 compounds Chemical class 0.000 claims description 42
• VZCYOOQTPOCHFL-OWOJBTEDSA-N fumaric acid group Chemical group C(\C=C\C(=O)O)(=O)O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 42
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 41
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 38
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
• 235000013305 food Nutrition 0.000 claims description 26
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 26
• FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical group OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims description 24
• 239000003814 drug Substances 0.000 claims description 24
• 229940048879 dl tartaric acid Drugs 0.000 claims description 23
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
• 229910052739 hydrogen Inorganic materials 0.000 claims description 21
• 229910052760 oxygen Inorganic materials 0.000 claims description 20
• 239000008194 pharmaceutical composition Substances 0.000 claims description 20
• 239000002904 solvent Substances 0.000 claims description 20
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 19
• 239000001530 fumaric acid Substances 0.000 claims description 19
• 239000012047 saturated solution Substances 0.000 claims description 19
• 229960001270 d- tartaric acid Drugs 0.000 claims description 18
• 238000002844 melting Methods 0.000 claims description 18
• 230000008018 melting Effects 0.000 claims description 18
• 229960001367 tartaric acid Drugs 0.000 claims description 17
• 239000011975 tartaric acid Substances 0.000 claims description 17
• 235000002906 tartaric acid Nutrition 0.000 claims description 17
• 235000016709 nutrition Nutrition 0.000 claims description 15
• 235000013402 health food Nutrition 0.000 claims description 13
• 229910052721 tungsten Inorganic materials 0.000 claims description 11
• 208000024827 Alzheimer disease Diseases 0.000 claims description 10
• 208000002193 Pain Diseases 0.000 claims description 10
• 238000010438 heat treatment Methods 0.000 claims description 10
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
• 208000020925 Bipolar disease Diseases 0.000 claims description 9
• 206010012289 Dementia Diseases 0.000 claims description 8
• 208000028017 Psychotic disease Diseases 0.000 claims description 8
• 229910052796 boron Inorganic materials 0.000 claims description 8
• 208000022821 personality disease Diseases 0.000 claims description 8
• 208000019901 Anxiety disease Diseases 0.000 claims description 7
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 7
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 7
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 7
• 238000001816 cooling Methods 0.000 claims description 7
• 201000006062 Asperger syndrome Diseases 0.000 claims description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
• 208000000094 Chronic Pain Diseases 0.000 claims description 5
• 208000023105 Huntington disease Diseases 0.000 claims description 5
• 208000018737 Parkinson disease Diseases 0.000 claims description 5
• 208000029560 autism spectrum disease Diseases 0.000 claims description 5
• 201000003723 learning disability Diseases 0.000 claims description 5
• 208000028173 post-traumatic stress disease Diseases 0.000 claims description 5
• 206010012335 Dependence Diseases 0.000 claims description 4
• 208000030814 Eating disease Diseases 0.000 claims description 4
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
• 235000014632 disordered eating Nutrition 0.000 claims description 4
• 238000002360 preparation method Methods 0.000 claims description 4
• 208000022610 schizoaffective disease Diseases 0.000 claims description 4
• 208000000044 Amnesia Diseases 0.000 claims description 3
• 208000031091 Amnestic disease Diseases 0.000 claims description 3
• 208000020358 Learning disease Diseases 0.000 claims description 3
• 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
• 230000006986 amnesia Effects 0.000 claims description 3
• 238000002156 mixing Methods 0.000 claims description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
• 208000016686 tic disease Diseases 0.000 claims description 3
• 208000024254 Delusional disease Diseases 0.000 claims description 2
• 201000006347 Intellectual Disability Diseases 0.000 claims description 2
• 208000019568 Shared Paranoid disease Diseases 0.000 claims description 2
• 208000028810 Shared psychotic disease Diseases 0.000 claims description 2
• 208000002851 paranoid schizophrenia Diseases 0.000 claims description 2
• 150000001345 alkine derivatives Chemical class 0.000 claims 1
• HBNBMOGARBJBHS-UHFFFAOYSA-N dimethylarsane Chemical compound C[AsH]C HBNBMOGARBJBHS-UHFFFAOYSA-N 0.000 claims 1
• 238000011282 treatment Methods 0.000 abstract description 31
• 230000009467 reduction Effects 0.000 abstract description 6
• 125000000304 alkynyl group Chemical group 0.000 description 63
• 125000003118 aryl group Chemical group 0.000 description 61
• 125000000623 heterocyclic group Chemical group 0.000 description 52
• 125000004432 carbon atom Chemical group C* 0.000 description 50
• 241000699670 Mus sp. Species 0.000 description 48
• 125000005842 heteroatom Chemical group 0.000 description 47
• 125000001072 heteroaryl group Chemical group 0.000 description 44
• 230000000694 effects Effects 0.000 description 43
• 150000002332 glycine derivatives Chemical class 0.000 description 41
• 125000001424 substituent group Chemical group 0.000 description 38
• 208000017170 Lipid metabolism disease Diseases 0.000 description 33
• 125000004452 carbocyclyl group Chemical group 0.000 description 33
• 208000018914 glucose metabolism disease Diseases 0.000 description 33
• 239000000243 solution Substances 0.000 description 32
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 29
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 29
• 239000008103 glucose Substances 0.000 description 29
• 229910052757 nitrogen Inorganic materials 0.000 description 29
• 238000012360 testing method Methods 0.000 description 28
• 239000003795 chemical substances by application Substances 0.000 description 27
• 235000002639 sodium chloride Nutrition 0.000 description 27
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 23
• 150000003839 salts Chemical class 0.000 description 21
• 125000002837 carbocyclic group Chemical group 0.000 description 20
• 125000004435 hydrogen atom Chemical class [H]* 0.000 description 19
• 238000003756 stirring Methods 0.000 description 19
• 229910052717 sulfur Inorganic materials 0.000 description 18
• 239000004480 active ingredient Substances 0.000 description 17
• 239000000047 product Substances 0.000 description 17
• 239000000126 substance Substances 0.000 description 17
• 239000001257 hydrogen Substances 0.000 description 16
• 239000007787 solid Substances 0.000 description 16
• 239000002253 acid Substances 0.000 description 15
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 15
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 14
• 125000004122 cyclic group Chemical group 0.000 description 14
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 14
• 239000001301 oxygen Substances 0.000 description 14
• 239000011593 sulfur Substances 0.000 description 14
• 208000024891 symptom Diseases 0.000 description 14
• 239000000546 pharmaceutical excipient Substances 0.000 description 13
• 230000036278 prepulse Effects 0.000 description 13
• 238000004458 analytical method Methods 0.000 description 12
• 210000004027 cell Anatomy 0.000 description 12
• 125000004433 nitrogen atom Chemical group N* 0.000 description 12
• 208000011580 syndromic disease Diseases 0.000 description 12
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
• 230000008901 benefit Effects 0.000 description 11
• 125000000753 cycloalkyl group Chemical group 0.000 description 11
• 235000019441 ethanol Nutrition 0.000 description 11
• 102000004169 proteins and genes Human genes 0.000 description 11
• 108090000623 proteins and genes Proteins 0.000 description 11
• 239000012453 solvate Substances 0.000 description 11
• 230000001629 suppression Effects 0.000 description 11
• 238000005160 1H NMR spectroscopy Methods 0.000 description 10
• 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 10
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 10
• 239000004615 ingredient Substances 0.000 description 10
• 238000001308 synthesis method Methods 0.000 description 10
• 210000001519 tissue Anatomy 0.000 description 10
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 9
• 229910052799 carbon Inorganic materials 0.000 description 9
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
• 238000002411 thermogravimetry Methods 0.000 description 9
• 241000699666 Mus <mouse, genus> Species 0.000 description 8
• 208000012902 Nervous system disease Diseases 0.000 description 8
• 208000025966 Neurological disease Diseases 0.000 description 8
• 125000003710 aryl alkyl group Chemical group 0.000 description 8
• 239000002775 capsule Substances 0.000 description 8
• 150000001721 carbon Chemical group 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 238000002474 experimental method Methods 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 150000002500 ions Chemical class 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 8
• 230000037023 motor activity Effects 0.000 description 8
• 239000000843 powder Substances 0.000 description 8
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 201000004810 Vascular dementia Diseases 0.000 description 7
• 125000002619 bicyclic group Chemical group 0.000 description 7
• KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 7
• 239000000969 carrier Substances 0.000 description 7
• 229940088679 drug related substance Drugs 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 239000000651 prodrug Substances 0.000 description 7
• 229940002612 prodrug Drugs 0.000 description 7
• 238000011084 recovery Methods 0.000 description 7
• 238000006467 substitution reaction Methods 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 6
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
• 208000001089 Multiple system atrophy Diseases 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 239000008186 active pharmaceutical agent Substances 0.000 description 6
• 150000001412 amines Chemical class 0.000 description 6
• 229940050390 benzoate Drugs 0.000 description 6
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
• 210000004556 brain Anatomy 0.000 description 6
• 238000000576 coating method Methods 0.000 description 6
• 238000000113 differential scanning calorimetry Methods 0.000 description 6
• 239000002552 dosage form Substances 0.000 description 6
• 239000000796 flavoring agent Substances 0.000 description 6
• 229910052736 halogen Inorganic materials 0.000 description 6
• 150000002367 halogens Chemical class 0.000 description 6
• 239000008101 lactose Substances 0.000 description 6
• 229960001375 lactose Drugs 0.000 description 6
• 239000000314 lubricant Substances 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 239000003921 oil Substances 0.000 description 6
• 235000019198 oils Nutrition 0.000 description 6
• 206010013654 Drug abuse Diseases 0.000 description 5
• 229920002472 Starch Polymers 0.000 description 5
• 238000010521 absorption reaction Methods 0.000 description 5
• 239000002585 base Substances 0.000 description 5
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
• 208000015114 central nervous system disease Diseases 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 235000005911 diet Nutrition 0.000 description 5
• 238000004090 dissolution Methods 0.000 description 5
• 239000003995 emulsifying agent Substances 0.000 description 5
• 235000013355 food flavoring agent Nutrition 0.000 description 5
• 235000003599 food sweetener Nutrition 0.000 description 5
• 239000003701 inert diluent Substances 0.000 description 5
• 150000002632 lipids Chemical class 0.000 description 5
• 239000007937 lozenge Substances 0.000 description 5
• 125000006574 non-aromatic ring group Chemical group 0.000 description 5
• 125000004430 oxygen atom Chemical group O* 0.000 description 5
• 230000036407 pain Effects 0.000 description 5
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 5
• 239000006187 pill Substances 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 239000007909 solid dosage form Substances 0.000 description 5
• 230000006886 spatial memory Effects 0.000 description 5
• 235000019698 starch Nutrition 0.000 description 5
• 239000008107 starch Substances 0.000 description 5
• 239000003765 sweetening agent Substances 0.000 description 5
• 230000002194 synthesizing effect Effects 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• 238000002076 thermal analysis method Methods 0.000 description 5
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
• 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 4
• 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 description 4
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 4
• 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 4
• 125000002373 5 membered heterocyclic group Chemical group 0.000 description 4
• 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
• 125000004070 6 membered heterocyclic group Chemical group 0.000 description 4
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
• 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 4
• 208000012514 Cumulative Trauma disease Diseases 0.000 description 4
• 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 4
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
• 208000007465 Giant cell arteritis Diseases 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
• 229910002651 NO3 Inorganic materials 0.000 description 4
• 208000008589 Obesity Diseases 0.000 description 4
• 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 4
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• 208000000323 Tourette Syndrome Diseases 0.000 description 4
• NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
• 125000001931 aliphatic group Chemical group 0.000 description 4
• 125000004429 atom Chemical group 0.000 description 4
• 230000003542 behavioural effect Effects 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 230000002490 cerebral effect Effects 0.000 description 4
• 238000007796 conventional method Methods 0.000 description 4
• 238000002425 crystallisation Methods 0.000 description 4
• 230000008025 crystallization Effects 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 235000015872 dietary supplement Nutrition 0.000 description 4
• 239000000945 filler Substances 0.000 description 4
• 235000011187 glycerol Nutrition 0.000 description 4
• 229960005150 glycerol Drugs 0.000 description 4
• 208000013403 hyperactivity Diseases 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 125000002950 monocyclic group Chemical group 0.000 description 4
• 230000004899 motility Effects 0.000 description 4
• 235000020824 obesity Nutrition 0.000 description 4
• 230000003449 preventive effect Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 230000001681 protective effect Effects 0.000 description 4
• 229920006395 saturated elastomer Polymers 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 229960004793 sucrose Drugs 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 239000006188 syrup Substances 0.000 description 4
• 235000020357 syrup Nutrition 0.000 description 4
• 239000000080 wetting agent Substances 0.000 description 4
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 3
• 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 3
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
• 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 3
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 3
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
• 125000006164 6-membered heteroaryl group Chemical group 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
• 208000036640 Asperger disease Diseases 0.000 description 3
• 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• 206010011831 Cytomegalovirus infection Diseases 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• 206010020772 Hypertension Diseases 0.000 description 3
• 208000007031 Incontinentia pigmenti Diseases 0.000 description 3
• 206010022158 Injury to brachial plexus due to birth trauma Diseases 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
• 208000009829 Lewy Body Disease Diseases 0.000 description 3
• 201000002832 Lewy body dementia Diseases 0.000 description 3
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
• 208000005314 Multi-Infarct Dementia Diseases 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
• 206010031127 Orthostatic hypotension Diseases 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 208000000114 Pain Threshold Diseases 0.000 description 3
• 206010033799 Paralysis Diseases 0.000 description 3
• 229920005372 Plexiglas® Polymers 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 208000005587 Refsum Disease Diseases 0.000 description 3
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
• 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• 229940022663 acetate Drugs 0.000 description 3
• 239000000654 additive Substances 0.000 description 3
• 235000010443 alginic acid Nutrition 0.000 description 3
• 229920000615 alginic acid Polymers 0.000 description 3
• 125000005907 alkyl ester group Chemical group 0.000 description 3
• 125000000129 anionic group Chemical group 0.000 description 3
• 230000036506 anxiety Effects 0.000 description 3
• 230000006399 behavior Effects 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 230000037213 diet Effects 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
• 206010013663 drug dependence Diseases 0.000 description 3
• 208000024732 dysthymic disease Diseases 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 208000002980 facial hemiatrophy Diseases 0.000 description 3
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 229940050410 gluconate Drugs 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 150000004677 hydrates Chemical class 0.000 description 3
• 125000001041 indolyl group Chemical group 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 229910052500 inorganic mineral Inorganic materials 0.000 description 3
• 229940001447 lactate Drugs 0.000 description 3
• 235000010445 lecithin Nutrition 0.000 description 3
• 239000000787 lecithin Substances 0.000 description 3
• 229940067606 lecithin Drugs 0.000 description 3
• 239000008297 liquid dosage form Substances 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
• 150000004702 methyl esters Chemical class 0.000 description 3
• 235000013336 milk Nutrition 0.000 description 3
• 239000008267 milk Substances 0.000 description 3
• 210000004080 milk Anatomy 0.000 description 3
• 239000011707 mineral Substances 0.000 description 3
• 235000010755 mineral Nutrition 0.000 description 3
• 238000010172 mouse model Methods 0.000 description 3
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 230000037040 pain threshold Effects 0.000 description 3
• 208000019906 panic disease Diseases 0.000 description 3
• 208000033808 peripheral neuropathy Diseases 0.000 description 3
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 230000004962 physiological condition Effects 0.000 description 3
• 239000004926 polymethyl methacrylate Substances 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 125000006239 protecting group Chemical group 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 239000008247 solid mixture Substances 0.000 description 3
• 210000000278 spinal cord Anatomy 0.000 description 3
• 230000002269 spontaneous effect Effects 0.000 description 3
• 208000011117 substance-related disease Diseases 0.000 description 3
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 229940095064 tartrate Drugs 0.000 description 3
• 206010043207 temporal arteritis Diseases 0.000 description 3
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
• KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 3
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
• 238000012549 training Methods 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
• 229920002554 vinyl polymer Polymers 0.000 description 3
• 239000011782 vitamin Substances 0.000 description 3
• 235000013343 vitamin Nutrition 0.000 description 3
• 229930003231 vitamin Natural products 0.000 description 3
• 229940088594 vitamin Drugs 0.000 description 3
• 239000001993 wax Substances 0.000 description 3
• 229910052727 yttrium Inorganic materials 0.000 description 3
• 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 2
• 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 2
• 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 description 2
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
• 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 2
• LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 2
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
• LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
• MUAUTBNKPSNTFM-UHFFFAOYSA-N 2-phenylethyl carbamate Chemical compound NC(=O)OCCC1=CC=CC=C1 MUAUTBNKPSNTFM-UHFFFAOYSA-N 0.000 description 2
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 2
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 201000002882 Agraphia Diseases 0.000 description 2
• 208000007848 Alcoholism Diseases 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• 208000029197 Amphetamine-Related disease Diseases 0.000 description 2
• 206010002941 Apallic syndrome Diseases 0.000 description 2
• 206010003101 Arnold-Chiari Malformation Diseases 0.000 description 2
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 2
• 206010003805 Autism Diseases 0.000 description 2
• 208000020706 Autistic disease Diseases 0.000 description 2
• 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
• 208000034577 Benign intracranial hypertension Diseases 0.000 description 2
• KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
• 208000014644 Brain disease Diseases 0.000 description 2
• 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 2
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
• 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 2
• PJXUREXOINLASR-UHFFFAOYSA-N COC(N)=O.P Chemical compound COC(N)=O.P PJXUREXOINLASR-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 208000015321 Chiari malformation Diseases 0.000 description 2
• 206010008748 Chorea Diseases 0.000 description 2
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 208000022497 Cocaine-Related disease Diseases 0.000 description 2
• 208000001353 Coffin-Lowry syndrome Diseases 0.000 description 2
• 208000028698 Cognitive impairment Diseases 0.000 description 2
• 206010010071 Coma Diseases 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 208000014311 Cushing syndrome Diseases 0.000 description 2
• 229920000858 Cyclodextrin Polymers 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 2
• 206010019233 Headaches Diseases 0.000 description 2
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
• 208000007514 Herpes zoster Diseases 0.000 description 2
• 206010063491 Herpes zoster oticus Diseases 0.000 description 2
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 208000035150 Hypercholesterolemia Diseases 0.000 description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 description 2
• 206010021143 Hypoxia Diseases 0.000 description 2
• 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 2
• 208000008498 Infantile Refsum disease Diseases 0.000 description 2
• 206010021750 Infantile Spasms Diseases 0.000 description 2
• 208000018650 Intervertebral disc disease Diseases 0.000 description 2
• 208000028226 Krabbe disease Diseases 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• 201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 2
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 208000003863 Marijuana Abuse Diseases 0.000 description 2
• 201000002571 Melkersson-Rosenthal syndrome Diseases 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 201000002983 Mobius syndrome Diseases 0.000 description 2
• 206010069681 Monomelic amyotrophy Diseases 0.000 description 2
• 208000019022 Mood disease Diseases 0.000 description 2
• 208000026072 Motor neurone disease Diseases 0.000 description 2
• 201000002481 Myositis Diseases 0.000 description 2
• 208000010316 Myotonia congenita Diseases 0.000 description 2
• LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 208000008457 Neurologic Manifestations Diseases 0.000 description 2
• 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 2
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
• 208000020265 O'Sullivan-McLeod syndrome Diseases 0.000 description 2
• 208000026251 Opioid-Related disease Diseases 0.000 description 2
• 206010053854 Opsoclonus myoclonus Diseases 0.000 description 2
• 206010034912 Phobia Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
• 208000024777 Prion disease Diseases 0.000 description 2
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
• 208000021235 Schilder disease Diseases 0.000 description 2
• 208000030988 Schizoid Personality disease Diseases 0.000 description 2
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 201000003696 Sotos syndrome Diseases 0.000 description 2
• 208000005392 Spasm Diseases 0.000 description 2
• 208000029033 Spinal Cord disease Diseases 0.000 description 2
• 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 208000034799 Tauopathies Diseases 0.000 description 2
• 244000299461 Theobroma cacao Species 0.000 description 2
• 208000016620 Tourette disease Diseases 0.000 description 2
• 208000032109 Transient ischaemic attack Diseases 0.000 description 2
• 206010063661 Vascular encephalopathy Diseases 0.000 description 2
• 201000006791 West syndrome Diseases 0.000 description 2
• 208000018839 Wilson disease Diseases 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
• 125000002015 acyclic group Chemical group 0.000 description 2
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 2
• 229940072056 alginate Drugs 0.000 description 2
• 150000001335 aliphatic alkanes Chemical class 0.000 description 2
• 229910052783 alkali metal Inorganic materials 0.000 description 2
• 150000001340 alkali metals Chemical class 0.000 description 2
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
• 150000001336 alkenes Chemical class 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
• UINZSQJVKLWNOU-UHFFFAOYSA-N amino diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(ON)OC1=CC=CC=C1 UINZSQJVKLWNOU-UHFFFAOYSA-N 0.000 description 2
• 150000008064 anhydrides Chemical class 0.000 description 2
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
• 201000007201 aphasia Diseases 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
• 235000013361 beverage Nutrition 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 235000015895 biscuits Nutrition 0.000 description 2
• 206010005159 blepharospasm Diseases 0.000 description 2
• 230000000744 blepharospasm Effects 0.000 description 2
• 201000006431 brachial plexus neuropathy Diseases 0.000 description 2
• 208000029028 brain injury Diseases 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000006172 buffering agent Substances 0.000 description 2
• 235000019437 butane-1,3-diol Nutrition 0.000 description 2
• XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
• 201000001843 cannabis dependence Diseases 0.000 description 2
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 235000013339 cereals Nutrition 0.000 description 2
• 239000000460 chlorine Substances 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• 235000019219 chocolate Nutrition 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
• 235000016213 coffee Nutrition 0.000 description 2
• 235000013353 coffee beverage Nutrition 0.000 description 2
• 208000010877 cognitive disease Diseases 0.000 description 2
• 230000003920 cognitive function Effects 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 2
• 238000004031 devitrification Methods 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 235000019700 dicalcium phosphate Nutrition 0.000 description 2
• 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
• 230000000378 dietary effect Effects 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 239000002612 dispersion medium Substances 0.000 description 2
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
• 229940043264 dodecyl sulfate Drugs 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 206010058319 dysgraphia Diseases 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 206010014599 encephalitis Diseases 0.000 description 2
• 238000009505 enteric coating Methods 0.000 description 2
• 239000002702 enteric coating Substances 0.000 description 2
• 206010015037 epilepsy Diseases 0.000 description 2
• 125000004494 ethyl ester group Chemical group 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 230000021824 exploration behavior Effects 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 201000011349 geniculate herpes zoster Diseases 0.000 description 2
• 150000004820 halides Chemical class 0.000 description 2
• 231100000869 headache Toxicity 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 230000007407 health benefit Effects 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• 208000003906 hydrocephalus Diseases 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 235000015110 jellies Nutrition 0.000 description 2
• 239000008274 jelly Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 239000012669 liquid formulation Substances 0.000 description 2
• 229940049920 malate Drugs 0.000 description 2
• BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 230000006386 memory function Effects 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
• VLKZOEOYAKHREP-UHFFFAOYSA-N methyl pentane Natural products CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 2
• 208000005264 motor neuron disease Diseases 0.000 description 2
• 206010065579 multifocal motor neuropathy Diseases 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 201000010193 neural tube defect Diseases 0.000 description 2
• 208000004296 neuralgia Diseases 0.000 description 2
• 208000021722 neuropathic pain Diseases 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 230000035764 nutrition Effects 0.000 description 2
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 230000000737 periodic effect Effects 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 208000005026 persistent vegetative state Diseases 0.000 description 2
• LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000011574 phosphorus Substances 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 150000003077 polyols Chemical class 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• LFULEKSKNZEWOE-UHFFFAOYSA-N propanil Chemical compound CCC(=O)NC1=CC=C(Cl)C(Cl)=C1 LFULEKSKNZEWOE-UHFFFAOYSA-N 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 229960004063 propylene glycol Drugs 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 208000001381 pseudotumor cerebri Diseases 0.000 description 2
• 230000006340 racemization Effects 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 229940043230 sarcosine Drugs 0.000 description 2
• 239000012056 semi-solid material Substances 0.000 description 2
• 229910052710 silicon Inorganic materials 0.000 description 2
• 239000010703 silicon Substances 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• 239000011343 solid material Substances 0.000 description 2
• 235000010356 sorbitol Nutrition 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 238000001179 sorption measurement Methods 0.000 description 2
• 206010062261 spinal cord neoplasm Diseases 0.000 description 2
• 208000002320 spinal muscular atrophy Diseases 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 201000009032 substance abuse Diseases 0.000 description 2
• 125000000547 substituted alkyl group Chemical group 0.000 description 2
• 125000003107 substituted aryl group Chemical group 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 238000004441 surface measurement Methods 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 206010042772 syncope Diseases 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 238000003419 tautomerization reaction Methods 0.000 description 2
• 238000010998 test method Methods 0.000 description 2
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
• 229940125725 tranquilizer Drugs 0.000 description 2
• 239000003204 tranquilizing agent Substances 0.000 description 2
• 230000002936 tranquilizing effect Effects 0.000 description 2
• 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
• 208000006961 tropical spastic paraparesis Diseases 0.000 description 2
• 208000009999 tuberous sclerosis Diseases 0.000 description 2
• 229940070710 valerate Drugs 0.000 description 2
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 230000031836 visual learning Effects 0.000 description 2
• 208000006542 von Hippel-Lindau disease Diseases 0.000 description 2
• 229920001285 xanthan gum Polymers 0.000 description 2
• 239000000230 xanthan gum Substances 0.000 description 2
• 235000010493 xanthan gum Nutrition 0.000 description 2
• 229940082509 xanthan gum Drugs 0.000 description 2
• AFCTUKSQTSHXEZ-UHFFFAOYSA-N (1-cyano-2-methylpropan-2-yl) carbamate Chemical compound N#CCC(C)(C)OC(N)=O AFCTUKSQTSHXEZ-UHFFFAOYSA-N 0.000 description 1
• KLWCNEYVHPBUNM-UHFFFAOYSA-N (1-methylcyclobutyl) carbamate Chemical compound NC(=O)OC1(C)CCC1 KLWCNEYVHPBUNM-UHFFFAOYSA-N 0.000 description 1
• AKIHTGIGOHBKGE-UHFFFAOYSA-N (1-methylcyclohexyl) carbamate Chemical compound NC(=O)OC1(C)CCCCC1 AKIHTGIGOHBKGE-UHFFFAOYSA-N 0.000 description 1
• KJOPTLWVYZCJBX-UHFFFAOYSA-N (2,4,6-trimethylphenyl)methyl carbamate Chemical compound CC1=CC(C)=C(COC(N)=O)C(C)=C1 KJOPTLWVYZCJBX-UHFFFAOYSA-N 0.000 description 1
• ZXAHGYAWWRSZMC-UHFFFAOYSA-N (2,4-dimethylthiophen-3-yl)carbamic acid Chemical compound CC1=CSC(C)=C1NC(O)=O ZXAHGYAWWRSZMC-UHFFFAOYSA-N 0.000 description 1
• SWHAGWLVMRLFKO-UHFFFAOYSA-N (2-nitrophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1[N+]([O-])=O SWHAGWLVMRLFKO-UHFFFAOYSA-N 0.000 description 1
• WMRLMOBINDQAOE-UHFFFAOYSA-N (3-nitrophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC([N+]([O-])=O)=C1 WMRLMOBINDQAOE-UHFFFAOYSA-N 0.000 description 1
• WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical compound [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 1
• AWOKSNNHYRGYIA-UHFFFAOYSA-N (4,5-dimethoxy-2-nitrophenyl)methyl carbamate Chemical compound COC1=CC(COC(N)=O)=C([N+]([O-])=O)C=C1OC AWOKSNNHYRGYIA-UHFFFAOYSA-N 0.000 description 1
• XHTUZBFAOYRMHI-UHFFFAOYSA-N (4-bromophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(Br)C=C1 XHTUZBFAOYRMHI-UHFFFAOYSA-N 0.000 description 1
• SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 1
• HIIOEWGKFCWTJU-UHFFFAOYSA-N (4-chlorophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(Cl)C=C1 HIIOEWGKFCWTJU-UHFFFAOYSA-N 0.000 description 1
• NULWVEYYQSYAHP-UHFFFAOYSA-N (4-cyanophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(C#N)C=C1 NULWVEYYQSYAHP-UHFFFAOYSA-N 0.000 description 1
• IERCGNSLWQVTPC-UHFFFAOYSA-N (4-decoxyphenyl)methyl carbamate Chemical compound CCCCCCCCCCOC1=CC=C(COC(N)=O)C=C1 IERCGNSLWQVTPC-UHFFFAOYSA-N 0.000 description 1
• ZGDWQQIXRCQCLZ-UHFFFAOYSA-N (4-ethoxynaphthalen-1-yl) hydrogen carbonate Chemical compound C1=CC=C2C(OCC)=CC=C(OC(O)=O)C2=C1 ZGDWQQIXRCQCLZ-UHFFFAOYSA-N 0.000 description 1
• OKLFHGKWEQKSDZ-UHFFFAOYSA-N (4-methoxyphenyl)methanimine Chemical compound COC1=CC=C(C=N)C=C1 OKLFHGKWEQKSDZ-UHFFFAOYSA-N 0.000 description 1
• LRJOVUGHUMSKFA-UHFFFAOYSA-N (4-nitrophenyl)methanimine Chemical compound [O-][N+](=O)C1=CC=C(C=N)C=C1 LRJOVUGHUMSKFA-UHFFFAOYSA-N 0.000 description 1
• FPBOSUGVPBRYCA-UHFFFAOYSA-N (4-nitrophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C([N+]([O-])=O)C=C1 FPBOSUGVPBRYCA-UHFFFAOYSA-N 0.000 description 1
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
• 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 1
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
• DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical class C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
• ZOJKRWXDNYZASL-NSCUHMNNSA-N (e)-4-methoxybut-2-enoic acid Chemical compound COC\C=C\C(O)=O ZOJKRWXDNYZASL-NSCUHMNNSA-N 0.000 description 1
• UPNNXUSUOSTIIM-UHFFFAOYSA-N 1,2-dithietane Chemical compound C1CSS1 UPNNXUSUOSTIIM-UHFFFAOYSA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• KVHYECHFPMHRKQ-UHFFFAOYSA-N 1,3-dimethyl-1,3,5-triazinan-2-one Chemical group CN1CNCN(C)C1=O KVHYECHFPMHRKQ-UHFFFAOYSA-N 0.000 description 1
• MNCMBBIFTVWHIP-UHFFFAOYSA-N 1-anthracen-9-yl-2,2,2-trifluoroethanone Chemical group C1=CC=C2C(C(=O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 MNCMBBIFTVWHIP-UHFFFAOYSA-N 0.000 description 1
• JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
• UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
• LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• 125000006017 1-propenyl group Chemical group 0.000 description 1
• KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
• UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
• 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
• NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
• MJBSQLQOPRALIV-UHFFFAOYSA-N 2,4,6-trimethoxybenzamide Chemical compound COC1=CC(OC)=C(C(N)=O)C(OC)=C1 MJBSQLQOPRALIV-UHFFFAOYSA-N 0.000 description 1
• FFFIRKXTFQCCKJ-UHFFFAOYSA-M 2,4,6-trimethylbenzoate Chemical compound CC1=CC(C)=C(C([O-])=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-M 0.000 description 1
• 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
• YURLCYGZYWDCHL-UHFFFAOYSA-N 2-(2,6-dichloro-4-methylphenoxy)acetic acid Chemical compound CC1=CC(Cl)=C(OCC(O)=O)C(Cl)=C1 YURLCYGZYWDCHL-UHFFFAOYSA-N 0.000 description 1
• DVCVYHFEWYAJCP-UHFFFAOYSA-N 2-(2-nitrophenoxy)acetamide Chemical compound NC(=O)COC1=CC=CC=C1[N+]([O-])=O DVCVYHFEWYAJCP-UHFFFAOYSA-N 0.000 description 1
• 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
• IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
• UJRMHFPTLFNSTA-UHFFFAOYSA-N 2-chloro-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(Cl)(C(=O)O)C1=CC=CC=C1 UJRMHFPTLFNSTA-UHFFFAOYSA-N 0.000 description 1
• CJNZAXGUTKBIHP-UHFFFAOYSA-M 2-iodobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-M 0.000 description 1
• UYCIUCIKUGYNBR-UHFFFAOYSA-N 2-iodoethyl carbamate Chemical compound NC(=O)OCCI UYCIUCIKUGYNBR-UHFFFAOYSA-N 0.000 description 1
• SDJNOBUNFYNROE-UHFFFAOYSA-N 2-methylbut-3-yn-2-yl carbamate Chemical compound C#CC(C)(C)OC(N)=O SDJNOBUNFYNROE-UHFFFAOYSA-N 0.000 description 1
• BRUZQRBVNRKLJG-UHFFFAOYSA-N 2-methylpropyl carbamate Chemical compound CC(C)COC(N)=O BRUZQRBVNRKLJG-UHFFFAOYSA-N 0.000 description 1
• OWXVECVXBTWHPP-UHFFFAOYSA-N 2-methylsulfanylethyl carbamate Chemical compound CSCCOC(N)=O OWXVECVXBTWHPP-UHFFFAOYSA-N 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical compound NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 1
• MZASHBBAFBWNFL-UHFFFAOYSA-N 2-trimethylsilylethanesulfonamide Chemical compound C[Si](C)(C)CCS(N)(=O)=O MZASHBBAFBWNFL-UHFFFAOYSA-N 0.000 description 1
• GPVOTFQILZVCFP-UHFFFAOYSA-N 2-trityloxyacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)O)C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• 125000001627 3 membered heterocyclic group Chemical group 0.000 description 1
• 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
• PPIXDIXXOMMDEI-UHFFFAOYSA-N 3,5-dinitro-3h-pyridin-4-one Chemical class [O-][N+](=O)C1C=NC=C([N+]([O-])=O)C1=O PPIXDIXXOMMDEI-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• KBRSJPHSCOAFDR-UHFFFAOYSA-N 3-chloro-6-methyl-5,5-dioxo-11h-benzo[c][2,1]benzothiazepin-11-ol Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(O)C2=CC=C(Cl)C=C21 KBRSJPHSCOAFDR-UHFFFAOYSA-N 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• SOYBEXQHNURCGE-UHFFFAOYSA-N 3-ethoxypropan-1-amine Chemical compound CCOCCCN SOYBEXQHNURCGE-UHFFFAOYSA-N 0.000 description 1
• 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
• UIYSCXBCJJMZQR-UHFFFAOYSA-N 33100-15-1 Chemical compound NCCC1=CC=CC=C1[N+]([O-])=O UIYSCXBCJJMZQR-UHFFFAOYSA-N 0.000 description 1
• 125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
• UBARRNXCKBFUEN-UHFFFAOYSA-N 4,5-diphenyl-5h-1,3-oxazol-2-one Chemical compound N=1C(=O)OC(C=2C=CC=CC=2)C=1C1=CC=CC=C1 UBARRNXCKBFUEN-UHFFFAOYSA-N 0.000 description 1
• HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
• WAGMYTXJRVPMGW-UHFFFAOYSA-N 4-azidobutanoic acid Chemical compound OC(=O)CCCN=[N+]=[N-] WAGMYTXJRVPMGW-UHFFFAOYSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• FUECBZYXGRQZRU-UHFFFAOYSA-N 4-methoxy-2,3,5,6-tetramethylbenzamide Chemical compound COC1=C(C)C(C)=C(C(N)=O)C(C)=C1C FUECBZYXGRQZRU-UHFFFAOYSA-N 0.000 description 1
• GUCPYIYFQVTFSI-UHFFFAOYSA-N 4-methoxybenzamide Chemical compound COC1=CC=C(C(N)=O)C=C1 GUCPYIYFQVTFSI-UHFFFAOYSA-N 0.000 description 1
• KHKJLJHJTQRHSA-UHFFFAOYSA-N 4-methyl-4-nitropentanoic acid Chemical compound [O-][N+](=O)C(C)(C)CCC(O)=O KHKJLJHJTQRHSA-UHFFFAOYSA-N 0.000 description 1
• JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
• JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 1
• NNJMFJSKMRYHSR-UHFFFAOYSA-M 4-phenylbenzoate Chemical compound C1=CC(C(=O)[O-])=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-M 0.000 description 1
• CDDGRARTNILYAB-UHFFFAOYSA-N 5,5-dimethylcyclohex-2-en-1-one Chemical compound CC1(C)CC=CC(=O)C1 CDDGRARTNILYAB-UHFFFAOYSA-N 0.000 description 1
• 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
• 206010052075 Acquired epileptic aphasia Diseases 0.000 description 1
• 102100031260 Acyl-coenzyme A thioesterase THEM4 Human genes 0.000 description 1
• 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 208000006888 Agnosia Diseases 0.000 description 1
• 241001047040 Agnosia Species 0.000 description 1
• 208000008811 Agoraphobia Diseases 0.000 description 1
• 208000024341 Aicardi syndrome Diseases 0.000 description 1
• 208000011403 Alexander disease Diseases 0.000 description 1
• VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical class NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• 208000036022 Alpers' disease Diseases 0.000 description 1
• 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
• 208000009575 Angelman syndrome Diseases 0.000 description 1
• 208000000103 Anorexia Nervosa Diseases 0.000 description 1
• 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
• 206010002660 Anoxia Diseases 0.000 description 1
• 241000976983 Anoxia Species 0.000 description 1
• 240000004178 Anthoxanthum odoratum Species 0.000 description 1
• 206010003062 Apraxia Diseases 0.000 description 1
• 208000022316 Arachnoid cyst Diseases 0.000 description 1
• 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
• 229910017008 AsF 6 Inorganic materials 0.000 description 1
• 102000007371 Ataxin-3 Human genes 0.000 description 1
• 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
• 235000007319 Avena orientalis Nutrition 0.000 description 1
• 244000075850 Avena orientalis Species 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 208000006373 Bell palsy Diseases 0.000 description 1
• 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
• 206010006074 Brachial plexus injury Diseases 0.000 description 1
• 208000004020 Brain Abscess Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 208000021465 Brief psychotic disease Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 206010006491 Brown-Sequard syndrome Diseases 0.000 description 1
• 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
• 208000032841 Bulimia Diseases 0.000 description 1
• 206010006550 Bulimia nervosa Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• UGHPLGZMZCPZAO-IBGZPJMESA-N C(C)N([C@@H](CCSC)C(=O)O)C1=CC=CC=2C3=CC=CC=C3CC12 Chemical class C(C)N([C@@H](CCSC)C(=O)O)C1=CC=CC=2C3=CC=CC=C3CC12 UGHPLGZMZCPZAO-IBGZPJMESA-N 0.000 description 1
• AKZQZSWKCXIOIS-UHFFFAOYSA-N C1=CC=C(C=C1)P(C2=CC=CC=C2)SP(=O)(O)O Chemical compound C1=CC=C(C=C1)P(C2=CC=CC=C2)SP(=O)(O)O AKZQZSWKCXIOIS-UHFFFAOYSA-N 0.000 description 1
• VAURRARZZSIFKR-UHFFFAOYSA-N C1C=C(C=CC1=O)C2=C(C=CC=C2Cl)COC(=O)N Chemical compound C1C=C(C=CC1=O)C2=C(C=CC=C2Cl)COC(=O)N VAURRARZZSIFKR-UHFFFAOYSA-N 0.000 description 1
• 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
• CDBBFGLZULAOLV-UHFFFAOYSA-N CN(C=O)C.C(N)(O)=O Chemical compound CN(C=O)C.C(N)(O)=O CDBBFGLZULAOLV-UHFFFAOYSA-N 0.000 description 1
• HDAQGQOHKKROBP-UHFFFAOYSA-N COC1=C(C2=C(C=C1)C3=CC=CC=C3C2)OC(=O)C4=CC=CC=C4 Chemical compound COC1=C(C2=C(C=C1)C3=CC=CC=C3C2)OC(=O)C4=CC=CC=C4 HDAQGQOHKKROBP-UHFFFAOYSA-N 0.000 description 1
• DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
• 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 208000022526 Canavan disease Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000001387 Causalgia Diseases 0.000 description 1
• 206010064012 Central pain syndrome Diseases 0.000 description 1
• 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
• 206010008096 Cerebral atrophy Diseases 0.000 description 1
• 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
• 206010008513 Child maltreatment syndrome Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000031640 Chromosome Fragility Diseases 0.000 description 1
• 235000001258 Cinchona calisaya Nutrition 0.000 description 1
• 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
• 229910020366 ClO 4 Inorganic materials 0.000 description 1
• 208000018652 Closed Head injury Diseases 0.000 description 1
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
• 208000027691 Conduct disease Diseases 0.000 description 1
• VPAXJOUATWLOPR-UHFFFAOYSA-N Conferone Chemical compound C1=CC(=O)OC2=CC(OCC3C4(C)CCC(=O)C(C)(C)C4CC=C3C)=CC=C21 VPAXJOUATWLOPR-UHFFFAOYSA-N 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
• 208000009283 Craniosynostoses Diseases 0.000 description 1
• 206010049889 Craniosynostosis Diseases 0.000 description 1
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• 206010011732 Cyst Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
• 206010012218 Delirium Diseases 0.000 description 1
• 208000020401 Depressive disease Diseases 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• 206010071545 Early infantile epileptic encephalopathy with burst-suppression Diseases 0.000 description 1
• 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 1
• 208000002403 Encephalocele Diseases 0.000 description 1
• 208000008967 Enuresis Diseases 0.000 description 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
• 208000024720 Fabry Disease Diseases 0.000 description 1
• 206010063006 Facial spasm Diseases 0.000 description 1
• 208000002091 Febrile Seizures Diseases 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• 208000024412 Friedreich ataxia Diseases 0.000 description 1
• 208000015872 Gaucher disease Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000011688 Generalised anxiety disease Diseases 0.000 description 1
• 208000007223 Gerstmann syndrome Diseases 0.000 description 1
• 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 208000009396 Group II Malformations of Cortical Development Diseases 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 208000004095 Hemifacial Spasm Diseases 0.000 description 1
• 101000638510 Homo sapiens Acyl-coenzyme A thioesterase THEM4 Proteins 0.000 description 1
• 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 208000037171 Hypercorticoidism Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000035899 Infantile spasms syndrome Diseases 0.000 description 1
• 208000001271 Inhalant Abuse Diseases 0.000 description 1
• 201000008450 Intracranial aneurysm Diseases 0.000 description 1
• 206010022773 Intracranial pressure increased Diseases 0.000 description 1
• 208000000209 Isaacs syndrome Diseases 0.000 description 1
• 201000008645 Joubert syndrome Diseases 0.000 description 1
• 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
• 208000027747 Kennedy disease Diseases 0.000 description 1
• 208000006541 Klippel-Feil syndrome Diseases 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• 208000005870 Lafora disease Diseases 0.000 description 1
• 208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 1
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
• 208000006136 Leigh Disease Diseases 0.000 description 1
• 208000017507 Leigh syndrome Diseases 0.000 description 1
• 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 206010048911 Lissencephaly Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 201000000251 Locked-in syndrome Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
• 239000005913 Maltodextrin Substances 0.000 description 1
• 229920002774 Maltodextrin Polymers 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000005767 Megalencephaly Diseases 0.000 description 1
• 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 1
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 208000027530 Meniere disease Diseases 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
• 208000012583 Menkes disease Diseases 0.000 description 1
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
• 206010027802 Moebius II syndrome Diseases 0.000 description 1
• 208000034167 Moebius syndrome Diseases 0.000 description 1
• 238000012347 Morris Water Maze Methods 0.000 description 1
• 208000009433 Moyamoya Disease Diseases 0.000 description 1
• 108010063954 Mucins Proteins 0.000 description 1
• 102000015728 Mucins Human genes 0.000 description 1
• 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
• 101100170604 Mus musculus Dmap1 gene Proteins 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• 208000008238 Muscle Spasticity Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 206010028424 Myasthenic syndrome Diseases 0.000 description 1
• 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
• 206010028570 Myelopathy Diseases 0.000 description 1
• 208000002033 Myoclonus Diseases 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• 208000012905 Myotonic disease Diseases 0.000 description 1
• UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 description 1
• 208000027120 Narcissistic personality disease Diseases 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
• 206010060860 Neurological symptom Diseases 0.000 description 1
• 206010072359 Neuromyotonia Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 206010057852 Nicotine dependence Diseases 0.000 description 1
• 208000014060 Niemann-Pick disease Diseases 0.000 description 1
• 102000007999 Nuclear Proteins Human genes 0.000 description 1
• 108010089610 Nuclear Proteins Proteins 0.000 description 1
• PFEWMOVPSABRTL-UHFFFAOYSA-N ON1CCCCC1.C(=O)(O)N Chemical compound ON1CCCCC1.C(=O)(O)N PFEWMOVPSABRTL-UHFFFAOYSA-N 0.000 description 1
• 206010068106 Occipital neuralgia Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 206010069350 Osmotic demyelination syndrome Diseases 0.000 description 1
• 206010056332 Panencephalitis Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 229920002230 Pectic acid Polymers 0.000 description 1
• 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
• 208000012202 Pervasive developmental disease Diseases 0.000 description 1
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
• 208000012641 Pigmentation disease Diseases 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 206010052469 Postictal paralysis Diseases 0.000 description 1
• 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
• 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
• 108010009736 Protein Hydrolysates Proteins 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
• 206010037180 Psychiatric symptoms Diseases 0.000 description 1
• 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
• LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Natural products C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
• 206010037779 Radiculopathy Diseases 0.000 description 1
• 208000032831 Ramsay Hunt syndrome Diseases 0.000 description 1
• 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
• 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
• 206010038584 Repetitive strain injury Diseases 0.000 description 1
• 208000005793 Restless legs syndrome Diseases 0.000 description 1
• 208000006289 Rett Syndrome Diseases 0.000 description 1
• 201000007981 Reye syndrome Diseases 0.000 description 1
• CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
• 208000021811 Sandhoff disease Diseases 0.000 description 1
• 229910018286 SbF 6 Inorganic materials 0.000 description 1
• 208000000729 Schizencephaly Diseases 0.000 description 1
• 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
• 241000555745 Sciuridae Species 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 206010039966 Senile dementia Diseases 0.000 description 1
• 208000000810 Separation Anxiety Diseases 0.000 description 1
• 208000002108 Shaken Baby Syndrome Diseases 0.000 description 1
• 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 206010041250 Social phobia Diseases 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 206010064387 Sotos' syndrome Diseases 0.000 description 1
• 206010041415 Spastic paralysis Diseases 0.000 description 1
• 201000010829 Spina bifida Diseases 0.000 description 1
• 208000006097 Spinal Dysraphism Diseases 0.000 description 1
• 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 208000010513 Stupor Diseases 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 239000004376 Sucralose Substances 0.000 description 1
• 208000027522 Sydenham chorea Diseases 0.000 description 1
• 206010042928 Syringomyelia Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
• 208000022292 Tay-Sachs disease Diseases 0.000 description 1
• 244000269722 Thea sinensis Species 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• 208000025569 Tobacco Use disease Diseases 0.000 description 1
• 206010043903 Tobacco abuse Diseases 0.000 description 1
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• 206010044696 Tropical spastic paresis Diseases 0.000 description 1
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
• 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 206010049644 Williams syndrome Diseases 0.000 description 1
• 210000001766 X chromosome Anatomy 0.000 description 1
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• 201000004525 Zellweger Syndrome Diseases 0.000 description 1
• 208000036813 Zellweger spectrum disease Diseases 0.000 description 1
• 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
• DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
• MAHKXOJNGNOVOH-UHFFFAOYSA-N [methoxy(phenyl)methyl] carbamate Chemical compound NC(=O)OC(OC)C1=CC=CC=C1 MAHKXOJNGNOVOH-UHFFFAOYSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• GCPWJFKTWGFEHH-UHFFFAOYSA-N acetoacetamide Chemical compound CC(=O)CC(N)=O GCPWJFKTWGFEHH-UHFFFAOYSA-N 0.000 description 1
• 150000008065 acid anhydrides Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 208000026345 acute stress disease Diseases 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 125000004423 acyloxy group Chemical group 0.000 description 1
• 125000005585 adamantoate group Chemical group 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 208000012826 adjustment disease Diseases 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
• 208000030597 adult Refsum disease Diseases 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 206010001584 alcohol abuse Diseases 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 208000025746 alcohol use disease Diseases 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000004450 alkenylene group Chemical group 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 125000004419 alkynylene group Chemical group 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• AEMOLEFTQBMNLQ-BKBMJHBISA-M alpha-D-galacturonate Chemical compound O[C@H]1O[C@H](C([O-])=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-M 0.000 description 1
• 208000011916 alternating hemiplegia Diseases 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 125000000320 amidine group Chemical group 0.000 description 1
• 150000001409 amidines Chemical class 0.000 description 1
• 125000006242 amine protecting group Chemical group 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 201000002472 amphetamine abuse Diseases 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 206010002320 anencephaly Diseases 0.000 description 1
• 208000000252 angiomatosis Diseases 0.000 description 1
• TZIHFWKZFHZASV-UHFFFAOYSA-N anhydrous methyl formate Natural products COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 230000007953 anoxia Effects 0.000 description 1
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
• FKFZOFZWJNHJDE-UHFFFAOYSA-N anthracene-9-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)N)=C(C=CC=C3)C3=CC2=C1 FKFZOFZWJNHJDE-UHFFFAOYSA-N 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000561 anti-psychotic effect Effects 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 208000024823 antisocial personality disease Diseases 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 206010003074 arachnoiditis Diseases 0.000 description 1
• 230000005744 arteriovenous malformation Effects 0.000 description 1
• 239000007961 artificial flavoring substance Substances 0.000 description 1
• 125000005228 aryl sulfonate group Chemical group 0.000 description 1
• 125000000732 arylene group Chemical group 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 230000000386 athletic effect Effects 0.000 description 1
• 230000009901 attention process Effects 0.000 description 1
• 210000003403 autonomic nervous system Anatomy 0.000 description 1
• 208000031375 autosomal dominant myotonia congenita Diseases 0.000 description 1
• 208000022804 avoidant personality disease Diseases 0.000 description 1
• 229940067597 azelate Drugs 0.000 description 1
• 125000003725 azepanyl group Chemical group 0.000 description 1
• 125000002785 azepinyl group Chemical group 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• DUXANUSOCMOJSI-UHFFFAOYSA-N benzhydryl carbamate Chemical compound C=1C=CC=CC=1C(OC(=O)N)C1=CC=CC=C1 DUXANUSOCMOJSI-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical class C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 208000030963 borderline personality disease Diseases 0.000 description 1
• 230000004641 brain development Effects 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 239000001273 butane Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 201000009322 cannabis abuse Diseases 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 150000001722 carbon compounds Chemical class 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 208000009885 central pontine myelinolysis Diseases 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 206010008129 cerebral palsy Diseases 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 229910052729 chemical element Inorganic materials 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
• 229940089960 chloroacetate Drugs 0.000 description 1
• FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
• MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical group OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
• 235000017803 cinnamon Nutrition 0.000 description 1
• 239000008199 coating composition Substances 0.000 description 1
• 201000001272 cocaine abuse Diseases 0.000 description 1
• 201000006145 cocaine dependence Diseases 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
• 229940125890 compound Ia Drugs 0.000 description 1
• JECGPMYZUFFYJW-UHFFFAOYSA-N conferone Natural products CC1=CCC2C(C)(C)C(=O)CCC2(C)C1COc3cccc4C=CC(=O)Oc34 JECGPMYZUFFYJW-UHFFFAOYSA-N 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 210000000877 corpus callosum Anatomy 0.000 description 1
• 239000006184 cosolvent Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 210000004714 cranial suture Anatomy 0.000 description 1
• LDHQCZJRKDOVOX-NSCUHMNNSA-M crotonate Chemical compound C\C=C\C([O-])=O LDHQCZJRKDOVOX-NSCUHMNNSA-M 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• LWABFMLTBBNLTA-UHFFFAOYSA-N cyclobutyl carbamate Chemical compound NC(=O)OC1CCC1 LWABFMLTBBNLTA-UHFFFAOYSA-N 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• VXVVUHQULXCUPF-UHFFFAOYSA-N cycloheptanamine Chemical compound NC1CCCCCC1 VXVVUHQULXCUPF-UHFFFAOYSA-N 0.000 description 1
• 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• AUELWJRRASQDKI-UHFFFAOYSA-N cyclohexyl carbamate Chemical compound NC(=O)OC1CCCCC1 AUELWJRRASQDKI-UHFFFAOYSA-N 0.000 description 1
• 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
• 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
• XGIBLEBJVMIPPF-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-1,3-dien-1-ylmethanamine iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.NCc1ccc[cH-]1 XGIBLEBJVMIPPF-UHFFFAOYSA-N 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• JMFVWNKPLURQMI-UHFFFAOYSA-N cyclopentyl carbamate Chemical class NC(=O)OC1CCCC1 JMFVWNKPLURQMI-UHFFFAOYSA-N 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• UWYRVVJXSNXVAI-UHFFFAOYSA-N cyclopropylmethyl carbamate Chemical compound NC(=O)OCC1CC1 UWYRVVJXSNXVAI-UHFFFAOYSA-N 0.000 description 1
• 208000026725 cyclothymic disease Diseases 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 235000013365 dairy product Nutrition 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 208000030964 dependent personality disease Diseases 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 229940120124 dichloroacetate Drugs 0.000 description 1
• JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
• 238000002050 diffraction method Methods 0.000 description 1
• 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
• 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
• 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
• 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
• 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 108700003601 dimethylglycine Proteins 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• 125000005879 dioxolanyl group Chemical group 0.000 description 1
• SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 125000005883 dithianyl group Chemical group 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000007905 drug manufacturing Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 208000019479 dysautonomia Diseases 0.000 description 1
• 206010013932 dyslexia Diseases 0.000 description 1
• 208000010118 dystonia Diseases 0.000 description 1
• 235000006694 eating habits Nutrition 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 150000002081 enamines Chemical class 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 239000004318 erythorbic acid Substances 0.000 description 1
• 235000010350 erythorbic acid Nutrition 0.000 description 1
• 201000006517 essential tremor Diseases 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• KWBIXTIBYFUAGV-UHFFFAOYSA-N ethylcarbamic acid Chemical compound CCNC(O)=O KWBIXTIBYFUAGV-UHFFFAOYSA-N 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 210000000744 eyelid Anatomy 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 235000021323 fish oil Nutrition 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• FGIVSGPRGVABAB-UHFFFAOYSA-N fluoren-9-ylmethyl hydrogen carbonate Chemical compound C1=CC=C2C(COC(=O)O)C3=CC=CC=C3C2=C1 FGIVSGPRGVABAB-UHFFFAOYSA-N 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 208000029364 generalized anxiety disease Diseases 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 150000002303 glucose derivatives Chemical class 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229940046257 glyceryl phosphate Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 201000002270 hallucinogen abuse Diseases 0.000 description 1
• 201000006138 hallucinogen dependence Diseases 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000012676 herbal extract Substances 0.000 description 1
• 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
• 125000005549 heteroarylene group Chemical group 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 235000019534 high fructose corn syrup Nutrition 0.000 description 1
• 208000009624 holoprosencephaly Diseases 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 201000009075 hydranencephaly Diseases 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 230000035863 hyperlocomotion Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 235000015243 ice cream Nutrition 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
• 210000003000 inclusion body Anatomy 0.000 description 1
• 201000008319 inclusion body myositis Diseases 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 238000002329 infrared spectrum Methods 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
• 201000009941 intracranial hypertension Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 229940026239 isoascorbic acid Drugs 0.000 description 1
• 125000005990 isobenzothienyl group Chemical group 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
• 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 206010023497 kuru Diseases 0.000 description 1
• 208000004343 lateral medullary syndrome Diseases 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 230000013016 learning Effects 0.000 description 1
• 208000036546 leukodystrophy Diseases 0.000 description 1
• 229940058352 levulinate Drugs 0.000 description 1
• 239000000944 linseed oil Substances 0.000 description 1
• 235000021388 linseed oil Nutrition 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 208000014817 lissencephaly spectrum disease Diseases 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 230000008376 long-term health Effects 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
• 208000024714 major depressive disease Diseases 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
• 239000000845 maltitol Substances 0.000 description 1
• 235000010449 maltitol Nutrition 0.000 description 1
• 229940035436 maltitol Drugs 0.000 description 1
• 229940035034 maltodextrin Drugs 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 230000015654 memory Effects 0.000 description 1
• 230000007087 memory ability Effects 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 206010027175 memory impairment Diseases 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
• NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
• RMIODHQZRUFFFF-UHFFFAOYSA-M methoxyacetate Chemical compound COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 description 1
• GPKUICFDWYEPTK-UHFFFAOYSA-N methoxycyclohexatriene Chemical group COC1=CC=C=C[CH]1 GPKUICFDWYEPTK-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 208000004141 microcephaly Diseases 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1
• 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 239000012452 mother liquor Substances 0.000 description 1
• 229940051875 mucins Drugs 0.000 description 1
• 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 230000020763 muscle atrophy Effects 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 210000003007 myelin sheath Anatomy 0.000 description 1
• 230000002151 myoclonic effect Effects 0.000 description 1
• MEPIGJGXDFBYLW-UHFFFAOYSA-N n-(2,4,6-trimethyl-3-pyridin-2-ylphenyl)methanimine Chemical compound CC1=C(N=C)C(C)=CC(C)=C1C1=CC=CC=N1 MEPIGJGXDFBYLW-UHFFFAOYSA-N 0.000 description 1
• BAYDZXVPEQFLCZ-UHFFFAOYSA-N n-(2-trimethylsilylethoxy)methanamine Chemical class CNOCC[Si](C)(C)C BAYDZXVPEQFLCZ-UHFFFAOYSA-N 0.000 description 1
• UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 1
• YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 description 1
• IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 1
• OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 201000003631 narcolepsy Diseases 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 210000000276 neural tube Anatomy 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 210000000715 neuromuscular junction Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 1
• 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 235000005152 nicotinamide Nutrition 0.000 description 1
• 239000011570 nicotinamide Substances 0.000 description 1
• 229960003966 nicotinamide Drugs 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical class N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 1
• 208000005346 nocturnal enuresis Diseases 0.000 description 1
• BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 239000002417 nutraceutical Substances 0.000 description 1
• 235000021436 nutraceutical agent Nutrition 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 235000014571 nuts Nutrition 0.000 description 1
• 125000001209 o-nitrophenyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])[N+]([O-])=O 0.000 description 1
• 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
• UZGLIIJVICEWHF-UHFFFAOYSA-N octogen Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)CN([N+]([O-])=O)C1 UZGLIIJVICEWHF-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
• 201000005040 opiate dependence Diseases 0.000 description 1
• 201000000988 opioid abuse Diseases 0.000 description 1
• 208000024196 oppositional defiant disease Diseases 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000003551 oxepanyl group Chemical group 0.000 description 1
• 125000003585 oxepinyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 125000000466 oxiranyl group Chemical group 0.000 description 1
• 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
• 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
• 208000005877 painful neuropathy Diseases 0.000 description 1
• 208000021090 palsy Diseases 0.000 description 1
• 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 208000027838 paramyotonia congenita of Von Eulenburg Diseases 0.000 description 1
• 208000024817 paranoid personality disease Diseases 0.000 description 1
• 208000035824 paresthesia Diseases 0.000 description 1
• 230000001314 paroxysmal effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 208000020930 peroxisome biogenesis disorder 1B Diseases 0.000 description 1
• 208000030591 peroxisome biogenesis disorder type 3B Diseases 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 238000009512 pharmaceutical packaging Methods 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
• 229950010883 phencyclidine Drugs 0.000 description 1
• 208000007100 phencyclidine abuse Diseases 0.000 description 1
• BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
• ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 description 1
• NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
• 208000019899 phobic disease Diseases 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• WLJVNTCWHIRURA-UHFFFAOYSA-M pimelate(1-) Chemical compound OC(=O)CCCCCC([O-])=O WLJVNTCWHIRURA-UHFFFAOYSA-M 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• 125000005547 pivalate group Chemical group 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 230000010287 polarization Effects 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 229920000155 polyglutamine Polymers 0.000 description 1
• 108010040003 polyglutamine Proteins 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 150000004804 polysaccharides Chemical class 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940068965 polysorbates Drugs 0.000 description 1
• 208000037955 postinfectious encephalomyelitis Diseases 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000018290 primary dysautonomia Diseases 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• RWUGBYOALBYTGU-UHFFFAOYSA-N pyridin-4-ylmethyl carbamate Chemical compound NC(=O)OCC1=CC=NC=C1 RWUGBYOALBYTGU-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 229960000948 quinine Drugs 0.000 description 1
• FLCPORVHXQFBHT-UHFFFAOYSA-N quinolin-8-yl carbamate Chemical compound C1=CN=C2C(OC(=O)N)=CC=CC2=C1 FLCPORVHXQFBHT-UHFFFAOYSA-N 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000000384 rearing effect Effects 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• YBKWIGSMABMNJZ-UHFFFAOYSA-N s-(2,3,4,5,6-pentachlorophenyl)thiohydroxylamine Chemical compound NSC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl YBKWIGSMABMNJZ-UHFFFAOYSA-N 0.000 description 1
• RTKRAORYZUBVGQ-UHFFFAOYSA-N s-(2,4-dinitrophenyl)thiohydroxylamine Chemical compound NSC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O RTKRAORYZUBVGQ-UHFFFAOYSA-N 0.000 description 1
• BDEZGPKAMAVGBE-UHFFFAOYSA-N s-(3-nitropyridin-2-yl)thiohydroxylamine Chemical compound NSC1=NC=CC=C1[N+]([O-])=O BDEZGPKAMAVGBE-UHFFFAOYSA-N 0.000 description 1
• DAXSYWBYJZACTA-UHFFFAOYSA-N s-(4-methoxy-2-nitrophenyl)thiohydroxylamine Chemical compound COC1=CC=C(SN)C([N+]([O-])=O)=C1 DAXSYWBYJZACTA-UHFFFAOYSA-N 0.000 description 1
• LOFZYSZWOLKUGE-UHFFFAOYSA-N s-benzyl carbamothioate Chemical compound NC(=O)SCC1=CC=CC=C1 LOFZYSZWOLKUGE-UHFFFAOYSA-N 0.000 description 1
• PIDYQAYNSQSDQY-UHFFFAOYSA-N s-tritylthiohydroxylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SN)C1=CC=CC=C1 PIDYQAYNSQSDQY-UHFFFAOYSA-N 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 229940116351 sebacate Drugs 0.000 description 1
• CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
• 230000009151 sensory gating Effects 0.000 description 1
• 208000025874 separation anxiety disease Diseases 0.000 description 1
• 208000002477 septooptic dysplasia Diseases 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 229910052814 silicon oxide Inorganic materials 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 208000019116 sleep disease Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 229940023144 sodium glycolate Drugs 0.000 description 1
• SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
• 235000014214 soft drink Nutrition 0.000 description 1
• 238000003797 solvolysis reaction Methods 0.000 description 1
• 229940075554 sorbate Drugs 0.000 description 1
• 208000018198 spasticity Diseases 0.000 description 1
• 201000001716 specific phobia Diseases 0.000 description 1
• 235000013599 spices Nutrition 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000024188 startle response Effects 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
• 201000006152 substance dependence Diseases 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 125000004426 substituted alkynyl group Chemical group 0.000 description 1
• BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
• 235000019408 sucralose Nutrition 0.000 description 1
• 238000000967 suction filtration Methods 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
• RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 201000006361 tethered spinal cord syndrome Diseases 0.000 description 1
• BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
• 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 230000008646 thermal stress Effects 0.000 description 1
• 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000005458 thianyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000001583 thiepanyl group Chemical group 0.000 description 1
• 125000003777 thiepinyl group Chemical group 0.000 description 1
• 125000002053 thietanyl group Chemical group 0.000 description 1
• 125000001730 thiiranyl group Chemical group 0.000 description 1
• 206010048627 thoracic outlet syndrome Diseases 0.000 description 1
• UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
• LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 201000010875 transient cerebral ischemia Diseases 0.000 description 1
• 208000009174 transverse myelitis Diseases 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 230000009529 traumatic brain injury Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000005881 triazolinyl group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 229940066528 trichloroacetate Drugs 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
• KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 210000003901 trigeminal nerve Anatomy 0.000 description 1
• 206010044652 trigeminal neuralgia Diseases 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 1
• JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
• 239000010937 tungsten Substances 0.000 description 1
• 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
• 208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• LVLANIHJQRZTPY-UHFFFAOYSA-N vinyl carbamate Chemical compound NC(=O)OC=C LVLANIHJQRZTPY-UHFFFAOYSA-N 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 235000013618 yogurt Nutrition 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1